We have published updated acceptable intake (AI) information for nitrosamine impurities in medicines consistent with recent EMA updated information. The changes include additional clarification for sponsors and manufacturers of the TGA’s expectations, minor editorial amendments, increases to the AI limit for some nitrosamine impurities and inclusion of recently internationally determined AI limits for numerous nitrosamine impurities in medicines.
